Theravance Biopharma, Inc. TBPH
Analyst Ratings
- Consensus
- Hold — 0 Buy · 6 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $16.33 (-4.1% downside)
Key Stats
- Today's Range
- $17.03 – $17.11
- 50-Day Range
- $16.41 – $17.74
- 52-Week Range
- $10.82 – $21.03
- Volume
- 487K shs
- Average Volume
- 549K shs
- Market Cap
- $884.18 million
- P/E Ratio
- 16.87
- Dividend Yield
- —
Valuation
- P/E Ratio
- 16.87
- Price / Book
- 3.05
- Price / Sales
- 8.48
Short Interest
- Short Interest
- 11.71%
- Days to Cover
- 46.12
Financials (TTM)
- Revenue
- $104.31 million
- Net Income
- $53.81 million
- Net Margin
- 51.58%
- Return on Equity
- 18.57%
- Debt-to-Equity
- —
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Related Stocks
Compare head-to-head: TBPH vs LLY·TBPH vs JNJ·TBPH vs ABBV·TBPH vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.